At about 20:00 on February 27, Heidelberg Pharma (HPHA), a German listed company, announced that it had signed an equity investment agreement and an exclusive product license agreement with Huadong Medicine Co.Ltd(000963) ( Huadong Medicine Co.Ltd(000963) ), and the two sides reached strategic cooperation. Heidelberg Pharma granted Huadong Medicine Co.Ltd(000963) two anti-tumor ATAC candidate drugs hdp-101 (multiple myeloma) and hdp-103 (prostate cancer) the exclusive development and commercialization rights in 20 Asian countries and regions, and the sole option of the other two anti-tumor ATAC candidate drugs hdp-102 and hdp-104, with a cooperation amount of up to $930 million.
© China Stock Market News